Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

Yusuf, HASAN; Islam, Shofiqul; Chow, Clara; Rangarajan, Sumathy; Dagenais, Gilles; Diaz, Rafael; Gupta, Rajeev; Kelishadi, Roya; Iqbal, Romaina; Avezum, Alvaro; Kruger, Annamarie; Kutty, Raman; Lanas, Fernando; Liu Lisheng, Liu; Wei, Li; Lopez-Jaramillo, Patricio; OĞUZ, AYTEKİN; Rahman, Omar; Swidan, Hany; Yusoff, Khalid; Zatonski, Witold; Rosengren, Annika; Teo, Koon

doi:10.1016/s0140-6736(11)61215-4

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

Atıf İçin Kopyala

Yusuf S., Islam S., Chow C. K., Rangarajan S., Dagenais G., Diaz R., ...Daha Fazla

LANCET, cilt.378, sa.9798, ss.1231-1243, 2011 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 378 Sayı: 9798
Basım Tarihi: 2011
Doi Numarası: 10.1016/s0140-6736(11)61215-4
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1231-1243
Ankara Üniversitesi Adresli: Evet

Özet

Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, beta blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke.